I actually looked the author up as well. I was pretty surprised that what seem to be pretty glaring grammatical errors made their way into what ostensibly is a pretty important article. I wonder if he would publish it with Forbes on the condition that nothing was reworded.

He’s also been critical of other drug trials, so it seems like this is something he does... seems like a reasonably trustworthy source.